Armour/Miles Factor VIII
Executive Summary
Rhone-Poulenc Rorer subsidiary will market Miles' recombinant Factor VIII for the treatment of hemophilia A. Under the terms of a January 1993 settlement of a patent dispute between the two companies ("The Pink Sheet" Feb. 8, 1993, In Brief), Miles will supply Armour with rFVIII, which Armour will sell under the name Helixate, which will be available in the second half of 1994. Armour's DDAVP nasal spray for mild hemophilia and von Willebrand's disease was cleared by FDA on March 7